Hitoshi Ohmori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hitoshi Ohmori has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Hiroki Kuniyasu
Department of Molecular Pathology, Nara Medical University, Kashihara, Nara 634‑8521, Japan
5 shared publications Kiyomu Fujii
Department of Molecular Pathology, Nara Medical University, Kashihara, Nara 634‑8521, Japan
3 shared publications- Takamitsu Sasaki
Department of Molecular Pathology, School of Medicine, Nara Medical University, Kashihara 634-8521, Japan
3 shared publications Eriko Tanabe
Department of Molecular Pathology, Nara Medical University, Kashihara, Nara 634‑8521, Japan
2 shared publicationsIsao Kawahara
Department of Molecular Pathology, Nara Medical University, Kashihara, Japan
2 shared publications- Kei Goto
Department of Rehabilitation, Steel Memorial Yawata Hospital
2 shared publications
Latest Publications
- Open Access
- 8 November 2019
- Published by S. Karger AG in Pathobiology
- Vol. 86 (5-6) , 306-314
Evaluation of Parameters for Cancer-Induced Sarcopenia in Patients Autopsied after Death from Colorectal Cancer
Cachexia frequently occurs in cancer patients and is correlated with reduced therapeutic responsiveness and poor prognosis. Although skeletal muscle atrophy is an important factor related to cachexia, biomarkers for its early diagnosis are not yet definitive. In this study, weight loss, body mass index, skeletal muscle index (SMI), serum carcinoembryonic antigen, serum tumor necrosis factor (TNF)-α, serum interleukin (IL)-6, serum high mobility group box (HMGB)-1, and SDS-soluble myosin light chain 1 (SDS-MYL1) of the psoas muscle were examined in 8 autopsied cases of death from colorectal cancer (CRC) as biomarkers of cachexia. SDS-MYL1 was positively correlated to SMI and TNF-α was negatively correlated, but the other factors did not show any correlations with SMI. Multivariate analysis showed that of the 3 cytokines, TNF-α and HMGB1 were correlated with SMI. Furthermore, when the biochemical skeletal muscle maturation marker, SDS-MYL1, was compared with serum cytokines, TNF-α and HMGB1 were negatively correlated but IL-6 was not. In multivariate analysis, only TNF-α was associated with SDS-MYL1. A positive correlation was found between TNF-α and HMGB1. These findings suggest that since TNF-α was inversely correlated with SMI and SDS-MYL1, TNF-α is a serum marker of skeletal muscle atrophy in CRC. Moreover, SDS-MYL1 might be established as a biomarker linked to clinical sarcopenia in experiments in vitro and in vivo.
- 8 November 2019
- Published by S. Karger AG in Pathobiology
- Vol. 86 (5-6) , 306-314
Open AccessEvaluation of Parameters for Cancer-Induced Sarcopenia in Patients Autopsied after Death from Colorectal Cancer
Cachexia frequently occurs in cancer patients and is correlated with reduced therapeutic responsiveness and poor prognosis. Although skeletal muscle atrophy is an important factor related to cachexia, biomarkers for its early diagnosis are not yet definitive. In this study, weight loss, body mass index, skeletal muscle index (SMI), serum carcinoembryonic antigen, serum tumor necrosis factor (TNF)-α, serum interleukin (IL)-6, serum high mobility group box (HMGB)-1, and SDS-soluble myosin light chain 1 (SDS-MYL1) of the psoas muscle were examined in 8 autopsied cases of death from colorectal cancer (CRC) as biomarkers of cachexia. SDS-MYL1 was positively correlated to SMI and TNF-α was negatively correlated, but the other factors did not show any correlations with SMI. Multivariate analysis showed that of the 3 cytokines, TNF-α and HMGB1 were correlated with SMI. Furthermore, when the biochemical skeletal muscle maturation marker, SDS-MYL1, was compared with serum cytokines, TNF-α and HMGB1 were negatively correlated but IL-6 was not. In multivariate analysis, only TNF-α was associated with SDS-MYL1. A positive correlation was found between TNF-α and HMGB1. These findings suggest that since TNF-α was inversely correlated with SMI and SDS-MYL1, TNF-α is a serum marker of skeletal muscle atrophy in CRC. Moreover, SDS-MYL1 might be established as a biomarker linked to clinical sarcopenia in experiments in vitro and in vivo.
- Open Access
- 29 March 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (6) , 8641-8646
Expression of long‑chain fatty acid receptor GPR40 is associated with cancer progression in colorectal cancer: A retrospective study
An increased risk of colorectal cancer (CRC) is associated with a western style diet, particularly hyperlipidemia. The expression of G‑protein coupled receptor 40 (GPR40), a membrane‑bound receptor for long‑chain fatty acids (LCFAs), was examined in 36 cases of subserosal‑invading CRC and compared with clinicopathological parameters as well as triglyceride (TG) and low‑density lipoprotein (LDL) levels in the blood. All patients with CRC expressed GPR40, which was positively associated with blood TG levels (P<0.0001) but not with blood LDL levels. GPR40 expression was positively associated with nodal metastasis, distant metastasis (particularly to the liver), stage and poor prognosis. Patients with high GPR40 expression and high TG levels had comparatively worse survival outcomes compared with patients with low GPR40 expression and low TG levels. The results of the present study suggest that activation of GPR40 may be associated with the progression and prognosis of CRCs. High levels of GPR40 and/or concurrent high levels of GPR40 and TG may be a risk for CRC progression.
- 29 March 2018
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (6) , 8641-8646
Open AccessExpression of long‑chain fatty acid receptor GPR40 is associated with cancer progression in colorectal cancer: A retrospective study
An increased risk of colorectal cancer (CRC) is associated with a western style diet, particularly hyperlipidemia. The expression of G‑protein coupled receptor 40 (GPR40), a membrane‑bound receptor for long‑chain fatty acids (LCFAs), was examined in 36 cases of subserosal‑invading CRC and compared with clinicopathological parameters as well as triglyceride (TG) and low‑density lipoprotein (LDL) levels in the blood. All patients with CRC expressed GPR40, which was positively associated with blood TG levels (P<0.0001) but not with blood LDL levels. GPR40 expression was positively associated with nodal metastasis, distant metastasis (particularly to the liver), stage and poor prognosis. Patients with high GPR40 expression and high TG levels had comparatively worse survival outcomes compared with patients with low GPR40 expression and low TG levels. The results of the present study suggest that activation of GPR40 may be associated with the progression and prognosis of CRCs. High levels of GPR40 and/or concurrent high levels of GPR40 and TG may be a risk for CRC progression.
- Open Access
- 17 May 2017
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (1) , 681-686
Fatty acids inhibit anticancer effects of 5-fluorouracil in mouse cancer cell lines
The present study investigated the effects of two major dietary fatty acid components, linoleic acid (LA) and elaidic acid (EA), on the antitumor effects of 5-fluorouracil (5‑FU) in the LL2, CT26 and CMT93 mouse cancer cell lines. Concurrent treatment with LA and 5‑FU elicited a decreased cell viability compared with treatment with 5‑FU alone. In addition, increased inhibition of growth was observed following concurrent treatment with EA and 5‑FU. Sequential treatment of LA followed by 5‑FU abrogated the anticancer effects of 5‑FU, and treatment with EA followed by 5‑FU increased cancer cell growth in addition to abrogating the anticancer effects of 5‑FU. The expression of the stem cell markers CD133 and nucleostemin (NS) increased in all three cell lines treated concurrently with 5‑FU and either LA or EA when compared with cells treated with 5‑FU alone. Aldehyde dehydrogenase activity in the cancer stem cells (CSCs), in response to concurrent treatment with 5‑FU and either LA or EA, was increased compared with 5‑FU treatment alone. 5‑FU inhibited the growth of CT26 tumors, but co‑treatment with either LA or EA abrogated this effect. NS‑positive CSCs were more abundant in CT26 tumors treated with 5‑FU and either LA or EA compared with those treated with 5‑FU alone. The results of the present study suggested that, rather than altering the sensitivity of cancer cells to 5‑FU, LA and EA may promote the survival of CSCs. The results indicated that dietary composition during chemotherapy is an important issue.
- 17 May 2017
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (1) , 681-686
Open AccessFatty acids inhibit anticancer effects of 5-fluorouracil in mouse cancer cell lines
The present study investigated the effects of two major dietary fatty acid components, linoleic acid (LA) and elaidic acid (EA), on the antitumor effects of 5-fluorouracil (5‑FU) in the LL2, CT26 and CMT93 mouse cancer cell lines. Concurrent treatment with LA and 5‑FU elicited a decreased cell viability compared with treatment with 5‑FU alone. In addition, increased inhibition of growth was observed following concurrent treatment with EA and 5‑FU. Sequential treatment of LA followed by 5‑FU abrogated the anticancer effects of 5‑FU, and treatment with EA followed by 5‑FU increased cancer cell growth in addition to abrogating the anticancer effects of 5‑FU. The expression of the stem cell markers CD133 and nucleostemin (NS) increased in all three cell lines treated concurrently with 5‑FU and either LA or EA when compared with cells treated with 5‑FU alone. Aldehyde dehydrogenase activity in the cancer stem cells (CSCs), in response to concurrent treatment with 5‑FU and either LA or EA, was increased compared with 5‑FU treatment alone. 5‑FU inhibited the growth of CT26 tumors, but co‑treatment with either LA or EA abrogated this effect. NS‑positive CSCs were more abundant in CT26 tumors treated with 5‑FU and either LA or EA compared with those treated with 5‑FU alone. The results of the present study suggested that, rather than altering the sensitivity of cancer cells to 5‑FU, LA and EA may promote the survival of CSCs. The results indicated that dietary composition during chemotherapy is an important issue.
- 1 December 2014
- Published by Elsevier in Journal of Surgical Research
- Vol. 192 (2) , 390-394
Serum CD10 is associated with liver metastasis in colorectal cancer
- 1 December 2014
- Published by Elsevier in Journal of Surgical Research
- Vol. 192 (2) , 390-394
Serum CD10 is associated with liver metastasis in colorectal cancer
- Open Access
- 28 August 2009
- Published by Wiley in Cell Proliferation
- Vol. 42 (5) , 701-709
Co‐treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells
Objectives: High‐mobility group box 1 (HMGB1) is a nuclear protein that acts as a ligand of the receptor for advanced glycation end products (RAGE) and its expression enhances progression of cancer. However, the mechanism underlying HMGB1 secretion is still unclear. In this study, we examined the effect of deoxycholic acid (DCA), a promoter of colon carcinogenesis, on HMGB1 secretion.Materials and Methods: We used an in vitro transformation model comprised of IEC6 intestinal epithelial cells treated with azoxymethane (AOM) and/or DCA. HMGB1 expression and secretion were examined by Western and Northern blot analyses, and ELISA. Intracellular translocation of HMGB1 was examined by protein fractionation.Results: AOM + DCA‐treated IEC6 cells showed upregulation of HMGB1 mRNA expression and increased level of HMGB1 protein in culture medium, but decreased level of HMGB1 protein in the nucleus. AOM + DCA treatment increased level of histone H4 acetylation, which induced translocation of HMGB1 from the nucleus to the cytoplasm and increased HMGB1 secretion. Leptomycin B inhibited extranuclear translocation and secretion of the HMGB1 protein.Conclusion: These findings suggest that DCA affects intracellular localization and secretion of HMGB1.
- 28 August 2009
- Published by Wiley in Cell Proliferation
- Vol. 42 (5) , 701-709
Open AccessCo‐treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells
Objectives: High‐mobility group box 1 (HMGB1) is a nuclear protein that acts as a ligand of the receptor for advanced glycation end products (RAGE) and its expression enhances progression of cancer. However, the mechanism underlying HMGB1 secretion is still unclear. In this study, we examined the effect of deoxycholic acid (DCA), a promoter of colon carcinogenesis, on HMGB1 secretion.Materials and Methods: We used an in vitro transformation model comprised of IEC6 intestinal epithelial cells treated with azoxymethane (AOM) and/or DCA. HMGB1 expression and secretion were examined by Western and Northern blot analyses, and ELISA. Intracellular translocation of HMGB1 was examined by protein fractionation.Results: AOM + DCA‐treated IEC6 cells showed upregulation of HMGB1 mRNA expression and increased level of HMGB1 protein in culture medium, but decreased level of HMGB1 protein in the nucleus. AOM + DCA treatment increased level of histone H4 acetylation, which induced translocation of HMGB1 from the nucleus to the cytoplasm and increased HMGB1 secretion. Leptomycin B inhibited extranuclear translocation and secretion of the HMGB1 protein.Conclusion: These findings suggest that DCA affects intracellular localization and secretion of HMGB1.
- 1 August 1993
- Published by Elsevier in Journal of Immunological Methods
- Vol. 164 (1) , 131-135
Enzyme release assay of human NK cell activity using β-galactosidase-expressing K562 target cell line
- 1 August 1993
- Published by Elsevier in Journal of Immunological Methods
- Vol. 164 (1) , 131-135
Enzyme release assay of human NK cell activity using β-galactosidase-expressing K562 target cell line
- 1 October 1992
- Published by Elsevier in Immunology Letters
- Vol. 34 (2) , 99-104
In vitro antigen-specific IgE response is refractory to suppression by interferon-γ
- 1 October 1992
- Published by Elsevier in Immunology Letters
- Vol. 34 (2) , 99-104
In vitro antigen-specific IgE response is refractory to suppression by interferon-γ